Do we need „cardio-metabolic“ specialists?

Czech version

Authors: Ján Murín
Authors‘ workplace: I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava
Published in: Diab Obez 2020; 20(40): 117-118
Category:

Sources

Buse JB, Wexler DJ, Tsapas A et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by American Diabetes Association and European Association for the Study of Diabetes. Diabetes Care 2020; 43(2): 487–493. Dostupné z DOI: <http://dx.doi.org/10.2337/dci19–0066>.
Cosentino F, Grant PJ, Aboyans V et al. [ESC Scientific Document Group]. 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2): 255–323. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.
Gunawan F, Partridge C, Kosiborod M et al. SUN-149 Cardiologist vs endocrinologist encounters in patients with T2DM and CVD: potential implications for glucose/lowering therapy use and education. J Endocr Soc 2019; 3(Suppl 1): SUN-149. Dostupné z DOI: <http://dx.doi.org/10.1210/js.2019-SUN-149>.
Arnold SV, Inzucchi SE, Tang F et al Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials:an NCDR(R) research to practice project. Eur J Prev Cardiol 2017; 24(15): 1637–1645. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487317729252>.
Zelniker TA, Wiwiott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393(10166): 31–39. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32590-X>.